ATE503756T1 - Pyrazoloä3,4-büpyridinverbindungen und ihre verwendung als pde4-inhibitoren - Google Patents

Pyrazoloä3,4-büpyridinverbindungen und ihre verwendung als pde4-inhibitoren

Info

Publication number: ATE503756T1
Authority: AT; Austria
Prior art keywords: methyl; compounds; nr15b; 6alkyl; het
Prior art date: 2005-09-29

Application number

AT06779578T

Other languages

English (en)

Inventor

Christopher Edlin

Stuart Holman

Paul Jones

Suzanne KEELING

Mika Lindvall

Charlotte Mitchell

Naimisha Trivedi

Original Assignee

Glaxo Group Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2005-09-29

Filing date

2006-09-29

Publication date

2011-04-15

2006-09-29 Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd

2011-04-15 Application granted granted Critical

2011-04-15 Publication of ATE503756T1 publication Critical patent/ATE503756T1/de

Links

150000001875 compounds Chemical class 0.000 title abstract 3
229940123932 Phosphodiesterase 4 inhibitor Drugs 0.000 title 1
239000002587 phosphodiesterase IV inhibitor Substances 0.000 title 1
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 3
-1 C1-2fluoroalkyl Chemical group 0.000 abstract 2
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 abstract 2
125000006273 (C1-C3) alkyl group Chemical group 0.000 abstract 1
208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 abstract 1
102000004861 Phosphoric Diester Hydrolases Human genes 0.000 abstract 1
108090001050 Phosphoric Diester Hydrolases Proteins 0.000 abstract 1
208000026935 allergic disease Diseases 0.000 abstract 1
125000004093 cyano group Chemical group *C#N 0.000 abstract 1
125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 abstract 1
125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 abstract 1
125000003709 fluoroalkyl group Chemical group 0.000 abstract 1
125000000623 heterocyclic group Chemical group 0.000 abstract 1
208000027866 inflammatory disease Diseases 0.000 abstract 1
230000002757 inflammatory effect Effects 0.000 abstract 1
239000003112 inhibitor Substances 0.000 abstract 1
125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 abstract 1
125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 abstract 1
238000011321 prophylaxis Methods 0.000 abstract 1
150000003839 salts Chemical class 0.000 abstract 1
238000011282 treatment Methods 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications

Landscapes

Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Pulmonology (AREA)
Dermatology (AREA)
Psychiatry (AREA)
Cardiology (AREA)
Hospice & Palliative Care (AREA)
Pain & Pain Management (AREA)
Immunology (AREA)
Rheumatology (AREA)
Heart & Thoracic Surgery (AREA)
Orthopedic Medicine & Surgery (AREA)
Toxicology (AREA)
Ophthalmology & Optometry (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Physical Education & Sports Medicine (AREA)
Urology & Nephrology (AREA)
Otolaryngology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Medicinal Preparation (AREA)

AT06779578T 2005-09-29 2006-09-29 Pyrazoloä3,4-büpyridinverbindungen und ihre verwendung als pde4-inhibitoren ATE503756T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US72159705P	2005-09-29	2005-09-29
PCT/GB2006/003626 WO2007036733A1 (en)	2005-09-29	2006-09-29	Pyrazolo[3,4-b]pyridine compounds, and their use as pde4 inhibitors

Publications (1)

Publication Number	Publication Date
ATE503756T1 true ATE503756T1 (de)	2011-04-15

Family

ID=37685723

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT06779578T ATE503756T1 (de)	2005-09-29	2006-09-29	Pyrazoloä3,4-büpyridinverbindungen und ihre verwendung als pde4-inhibitoren

Country Status (7)

Country	Link
US (2)	US20080255186A1 (de)
EP (2)	EP1940836A1 (de)
JP (2)	JP2009510044A (de)
AT (1)	ATE503756T1 (de)
DE (1)	DE602006021044D1 (de)
ES (1)	ES2363795T3 (de)
WO (2)	WO2007036733A1 (de)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ES2363795T3 (es) *	2005-09-29	2011-08-16	Glaxo Group Limited	Compuestos de pirazolo[3,4-b]piridina, y su uso como inhibidores de pde4.
GB0614570D0 (en) *	2006-07-21	2006-08-30	Glaxo Group Ltd	Compounds
PT2046787E (pt) *	2006-08-01	2011-06-15	Glaxo Group Ltd	Compostos de pirazolo[3,4-b]piridina e sua utilização como inibidores de pde4
PT2124944E (pt) *	2007-03-14	2012-05-17	Ranbaxy Lab Ltd	Derivados de pirazolo[3,4-b]piridina como inibidores de fosfodiesterase
EP2141150B1 (de)	2007-04-26	2013-12-11	Takeda Pharmaceutical Company Limited	Bicyclische verbindung und ihre pharmazeutische verwendung
WO2009100169A1 (en) *	2008-02-06	2009-08-13	Glaxo Group Limited	Dual pharmacophores - pde4-muscarinic antagonistics
WO2009100170A1 (en) *	2008-02-06	2009-08-13	Glaxo Group Limited	Dual pharmacophores - pde4-muscarinic antagonistics
AU2009306026A1 (en) *	2008-09-19	2010-04-29	Ranbaxy Laboratories Limited	Phosphodiestarase inhibitors
MX2011007499A (es)	2009-01-13	2011-08-04	Glaxo Group Ltd	Derivados de pirimidin-carboxamida como inhibidores de la cinasa syk.
MX2012010557A (es) *	2010-03-16	2012-10-05	Merck Patent Gmbh	Morfolinilquinazolinas.
US8487102B2 (en) *	2010-04-20	2013-07-16	Hoffmann-La Roche Inc.	Pyrrazolopyridine compounds as dual NK1/NK3 receptor antagonists
US20140113898A1 (en) *	2010-11-08	2014-04-24	Zalicus Pharmaceuticals Ltd.	Bisarylsulfone and dialkylarylsulfone compounds as calcium channel blockers
EP2574607A1 (de) *	2011-09-06	2013-04-03	F. Hoffmann-La Roche AG	PDE 10-Modulatoren
AU2014254392B2 (en) *	2013-03-15	2018-05-24	Epizyme, Inc.	Substituted benzene compounds
US9243001B2 (en)	2013-03-15	2016-01-26	Epizyme, Inc.	Substituted benzene compounds
US9011934B2 (en)	2013-06-14	2015-04-21	SatisPharma, LLC	Multi-purpose anti-itch treatment
EP3527569B1 (de)	2014-02-03	2021-08-25	Vitae Pharmaceuticals, LLC	Dihydropyrrolopyridininhibitoren von ror-gamma zur behandlung von augentrockenheit
DE102014009164A1 (de) *	2014-06-03	2015-12-03	Herbalist & Doc Gesundheitsgesellschaft Mbh	Silikonölhaltige nasal anzuwendende Formulierungen
TWI675032B (zh)	2014-10-14	2019-10-21	美商維它藥物公司	ＲＯＲ-γ之二氫吡咯并吡啶抑制劑
US9452178B1 (en)	2014-10-22	2016-09-27	SatisPharma, LLC	Acne formulations, treatments, and pressure sensitive patches for delivery of acne formulations
US9663515B2 (en)	2014-11-05	2017-05-30	Vitae Pharmaceuticals, Inc.	Dihydropyrrolopyridine inhibitors of ROR-gamma
US9845308B2 (en)	2014-11-05	2017-12-19	Vitae Pharmaceuticals, Inc.	Isoindoline inhibitors of ROR-gamma
ES2856931T3 (es)	2015-08-05	2021-09-28	Vitae Pharmaceuticals Llc	Moduladores de ROR-gamma
EP3868750A1 (de)	2015-11-20	2021-08-25	Vitae Pharmaceuticals, LLC	Modulatoren von ror-gamma
TW202220968A (zh)	2016-01-29	2022-06-01	美商維它藥物有限責任公司	ＲＯＲ－γ調節劑
US9481674B1 (en)	2016-06-10	2016-11-01	Vitae Pharmaceuticals, Inc.	Dihydropyrrolopyridine inhibitors of ROR-gamma
EP3558956B1 (de)	2016-12-20	2020-10-28	Syngenta Participations AG	N-cyclobutyl-thiazol-5-carboxamide mit nematizider wirkung
US11098010B2 (en)	2017-03-21	2021-08-24	Arbutus Biopharma Corporation	Substituted dihydroindene-4-carboxamides and analogs thereof, and methods using same
WO2019018975A1 (en)	2017-07-24	2019-01-31	Vitae Pharmaceuticals, Inc.	INHIBITORS OF ROR GAMMA
MA49685A (fr)	2017-07-24	2021-04-14	Vitae Pharmaceuticals Llc	INHIBITEURS DE ROR gamma
TW201920188A (zh) *	2017-08-10	2019-06-01	美商美國禮來大藥廠	[1,2,4]三唑衍生物
US12582809B2 (en)	2018-01-26	2026-03-24	Bt Bidco, Inc.	Treatment of a disease of the gastrointestinal tract with a PDE4 inhibitor
WO2020106757A1 (en)	2018-11-19	2020-05-28	Progenity, Inc.	Ingestible device for delivery of therapeutic agent to the gastrointestinal tract
CN121197633A (zh)	2019-12-13	2025-12-26	比特比德科有限责任公司	用于将治疗剂递送至胃肠道的可摄取装置
CN115335043B (zh) *	2020-01-23	2025-03-28	迈欧伏特治疗公司	Pgdh抑制剂以及制备和使用方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
PT1539753E (pt) *	2002-09-16	2009-12-10	Glaxo Group Ltd	Compostos de pirazolo(3,4-b)piridina e sua utilização como inibidores da fosfodiesterase
GB0230045D0 (en) *	2002-12-23	2003-01-29	Glaxo Group Ltd	Compounds
ES2363795T3 (es) *	2005-09-29	2011-08-16	Glaxo Group Limited	Compuestos de pirazolo[3,4-b]piridina, y su uso como inhibidores de pde4.

2006
- 2006-09-29 ES ES06779578T patent/ES2363795T3/es active Active
- 2006-09-29 EP EP06779579A patent/EP1940836A1/de not_active Withdrawn
- 2006-09-29 US US12/067,994 patent/US20080255186A1/en not_active Abandoned
- 2006-09-29 US US12/067,990 patent/US20090131431A1/en not_active Abandoned
- 2006-09-29 JP JP2008532874A patent/JP2009510044A/ja active Pending
- 2006-09-29 DE DE602006021044T patent/DE602006021044D1/de active Active
- 2006-09-29 AT AT06779578T patent/ATE503756T1/de not_active IP Right Cessation
- 2006-09-29 JP JP2008532873A patent/JP5323484B2/ja not_active Expired - Fee Related
- 2006-09-29 EP EP06779578A patent/EP1940835B1/de active Active
- 2006-09-29 WO PCT/GB2006/003626 patent/WO2007036733A1/en not_active Ceased
- 2006-09-29 WO PCT/GB2006/003627 patent/WO2007036734A1/en not_active Ceased

Also Published As

Publication number	Publication date
ES2363795T3 (es)	2011-08-16
DE602006021044D1 (de)	2011-05-12
JP5323484B2 (ja)	2013-10-23
WO2007036734A1 (en)	2007-04-05
WO2007036733A1 (en)	2007-04-05
US20090131431A1 (en)	2009-05-21
US20080255186A1 (en)	2008-10-16
EP1940836A1 (de)	2008-07-09
JP2009510043A (ja)	2009-03-12
JP2009510044A (ja)	2009-03-12
EP1940835B1 (de)	2011-03-30
EP1940835A1 (de)	2008-07-09

Legal Events

Date	Code	Title	Description
2011-09-15	RER	Ceased as to paragraph 5 lit. 3 law introducing patent treaties

Publication	Publication Date	Title
DE602006021044D1 (de)	2011-05-12	Pyrazoloä3,4-büpyridinverbindungen und ihre verwendung als pde4-inhibitoren
GT200600283A (es)	2007-02-14	COMPUESTOS DE AMINO-5-HETEROARILO (5 MIEMBROS) IMIDAZOLONA Y SU USO PARA LA MODULACIÓN DE LA beta-SECRETASA
DE60330362D1 (de)	2010-01-14	Neue pyrazol-verbindungen als hemmer des transformierenden wachstumsfaktors (tgf)
WO2007109456A3 (en)	2007-12-06	Substituted biphenyl isoxazole sulfonamides as dual angiotensin endothelin receptor antagonists
UA98116C2 (ru)	2012-04-25	Изоксазолины, композиция, их применение, способы получения и промежуточные соединения
DE60327443D1 (de)	2009-06-10	Neue oxazolverbindungen als inhibitoren des transforming growth factor (tgf)
EA200870409A1 (ru)	2009-04-28	Антагонисты киназы pi3
CL2009000576A1 (es)	2009-06-19	Un compuesto {1-etilsulfonil-3-[4-(7h-pirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il]azetidin-3-il}acetonitrilo o su sal; inhibidor de jak; composicion farmaceutica; y su uso para tratar artritis reumatoide.
WO2008039359A3 (en)	2008-05-08	Bicyclic pyrimidine kinase inhibitors
PE20051061A1 (es)	2005-12-12	5,7-DIAMINOPIRAZOLO[4,3-d] PIRIMIDINAS
PE20120814A1 (es)	2012-07-26	Compuestos y composiciones como inhibidores de la proteina cinasa
EA200700188A1 (ru)	2007-06-29	Производные замещенного 2-алкилхиназолинона как ингибиторы parp
NO20070122L (no)	2007-03-01	Quinazolinonderivater anvendelige som vanilloidantagonister
PE20060664A1 (es)	2006-08-04	Amidas biciclicas como inhibidores de cinasa
NI200900032A (es)	2010-05-14	Compuestos de pirido (2, 3-d) pirimidinonay su uso como inhibidores de pi3
ATE449761T1 (de)	2009-12-15	Heterocyclsche substituierte phenylmethanone als inhibitoren des glycintransporters 1
PE20070593A1 (es)	2007-07-23	Compuestos pirrolopirimidina como inhibidores de syk
BRPI0407082C1 (pt)	2021-05-25	composto n-(4-(1-(2,6-difluorobenzil)-5-((dimetilamino)metil)-3-(6-metóxi-3-piridazinil)-2,4-dioxo-1,2,3,4-tetraidrotieno[2,3-d]pirimidina-6-il)fenil)-n-metoxiuréia, ou um sal do mesmo, produto farmacêutico, e, uso do composto
PE20140226A1 (es)	2014-03-08	Compuestos de triazolopiridina
TW200744994A (en)	2007-12-16	Insecticidal 3-acylaminobenzanilides
EA201200891A1 (ru)	2013-01-30	Производные 3,4,4a,10d-тетрагидро-1h-тиопирано[4,3-c]изохинолина
EA201000612A1 (ru)	2010-10-29	Антагонисты cgrp-пептиды
WO2008053044A3 (de)	2008-09-12	Hetarylcarbonsäure-n-(biphen-2-yl)amid-verbindungen
EA201000494A1 (ru)	2010-08-30	Новые гидрокси-8-гетероарилфенантридины и их применение в качестве ингибиторов pde4
EA201001348A1 (ru)	2011-04-29	Пирролопиримидинкарбоксамиды